[CAS NO. 702662-50-8] STINGagonist-1

Name: STINGagonist-1
Brand: Arctom Scientific
SKU: HY-19711

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [702662-50-8]

Store

Catalog

HY-19711

Brand

MCE

CAS

702662-50-8

DESCRIPTION [702662-50-8]

Overview

MDL	MFCD04062826
Molecular Weight	430.88
Molecular Formula	C21H16ClFN2O3S
SMILES	O=C(C1=CC=C(SCC(N2CC3=C(F)C=CC=C3Cl)=O)C2=C1)NCC4=CC=CO4

For research use only. We do not sell to patients.

1 Publications Citing Use of MCE

[1]Patent. US20200268864A1.

Summary

STING agonist-1 (G10) is human-specific STING agonist that elicits antiviral activity against emerging Alphaviruses. G10 potently blocks replication of Alphavirus species Venezuelan Equine Encephalitis Virus (VEEV) with IC ₉₀ of 24.57 μM ^[1] .

IC50 & Target

IC90: 24.57 μM (VEEV) ^[1]

In Vitro

G10 induces IFN/IRF3- but not NF-κB-dependent transcription in human fibroblasts ^[1] .
G10 is an indirect activator of human STING-dependent phenotypes ^[1] .
G10-mediated IRF3 activation and anti-Alphaviral activity occur independently of IPS-1/MAVS-dependent signaling ^[1] .
STING is required for G10-mediated IRF3 activation, gene expression, and anti-Alphaviral activity ^[1] .
G10 induces STING-dependent synthesis and secretion of bioactive interferon ^[1] .
G10 induces innate antiviral mRNA expression in primary human cells ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03753022	Federal University of São Paulo\|Vanessa Marques Ferreira	Coronary Artery Disease\|Coronary Artery Bypass Grafting\|Acute Lung Injury	January 2012	Not Applicable

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 75 mg/mL ( 174.06 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.3208 mL	11.6042 mL	23.2083 mL
5 mM	0.4642 mL	2.3208 mL	4.6417 mL
10 mM	0.2321 mL	1.1604 mL	2.3208 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (5.80 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (5.80 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Sali TM, et al. Characterization of a Novel Human-Specific STING Agonist that Elicits Antiviral Activity Against Emerging Alphaviruses. PLoS Pathog. 2015 Dec 8;11(12):e1005324.